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Abstract
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Most traits of economical importance in animal production are quantitative i.e. they  are
characterized by a continuous variation of phenotypic values.  Examples for such  traits
are carcass weight, milk production and lean meat content. The phenotype  of an animal
for a quantitative trait depends on its genotype at several loci  (called quantitative  trait
loci, QTL) as well as on environmental factors. Up to date, a large number of QTLs have
been  identified  in  farm  animals  by  segregation  analysis  either  within  commercial
populations or in crossbreed populations. Animal geneticists face now the challenge  to
identify the causative mutations lying behind these QTLs.
In this thesis, we report the identification of the causative mutation for a  major  QTL
influencing muscle development, fat deposition and heart size in  pig. Previous  studies
have mapped this locus to the distal  end  of  pig  chromosome  2p.  Furthermore,  they
have hypothesized that the causative mutation(s)  may lie in an element regulating  the
expression  of  insulin-like  growth  factor  2  (IGF2).  Firstly,  we  sequenced  the  IGF2
region in the pig and made comparative sequence analysis with available human and
mouse  sequences.  We  then  used  an  identity-by-descent  approach  and  managed  to
pinpoint  the  causative  mutation  to  a  GA transition  located  in  an  evolutionary
conserved CpG island in IGF2 intron 3 (IGF2-intron3-G3070A). Subsequently, we used
electrophoretic mobility shift assay and transient transfection experiments and  showed
that  the  QTN  (quantitative  trait  nucleotide)  abrogates  the  binding  of  a  putative
repressor.  We completed our study by determining the core binding  site  of this  trans-
acting factor and by performing DNase I footprinting of the CpG island  containing  the
QTN. In addition, we identified an IGF2 antisense transcript (IGF2-AS) and showed that
its expression was also influenced by the QTN.
The discovery of mutations causing QTLs in farm animals opens great future prospects.
Besides evident practical breeding interests there  are also  major scientific  interests,  as
understanding  the  mechanism  causing  the  QTL  effects  will  broaden  our  general
knowledge on how the genome operates.
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Introduction
Most traits of economical importance in  animal production are quantitative i.e.
they are characterized by a continuous variation of phenotypic values. Examples
for such traits are carcass weight, milk  production and lean meat content. The
phenotype of an animal for a quantitative trait depends on its genotype at several
loci (called quantitative trait  loci,  QTL)  as  well  as  on  environmental factors
(Andersson, 2001). Up to date, a large number of QTLs have been identified in
farm animals by segregation analysis either within commercial populations or in
crossbreed populations. Animal geneticists face now the challenge to identify the
causative mutations lying behind these QTLs. The major obstacle is  the  poor
precision in the location of  those  loci.  Indeed, the  complex  relation between
genotype and  phenotype  complicates  the  detection  of  recombinants  between
markers and QTL as the genotype of an individual can only  be determined by
progeny testing. In addition, the nature of QTL mutations might complicate their
identification. QTLs are not responsible for disorders but only for mild variation
in phenotypic value and are therefore expected to be caused by a variant  gene
product or an altered gene expression rather than by a defect in gene product or in
gene expression. The causative mutation(s) can hence be regulatory or structural
and might be extremely difficult to distinguish from neutral  linked  mutations
(Georges & Andersson, 1996).
During  the  last  decades,  overweight  and  metabolic  disorders  have  been
increasing in western countries. As a consequence, the demand on “lighter” more
healthy products has also increased. This led the pig industry to select for animals
with higher lean muscle and reduced fat deposition. This  selection  goes  in
opposite direction to the one occurring on  wild  boars. Indeed, natural selection
favours animals that can store energy (i.e. fat), as those will  be able to  survive
periods of starvation. A three-generation intercross was made between wild boars
and Large White domestic pigs in an attempt to discover QTLs responsible for the
differences in  growth  and  fat  deposition  observed  between  those  animals
(Andersson et al., 1994; Andersson-Eklund et al., 1998). This successful approach
led  to  the  discovery  of  several  QTLs,  including  one  influencing  muscle
development, fat deposition and heart size.  This locus maps to the distal end of
pig chromosome  2p  (SSC2p)  and  has  the  particularity  of  being  imprinted
(maternally silenced). Early studies (Jeon et al., 1999; Nezer et al.,  1999) have
suggested IGF2 (insulin-like growth factor 2) as a candidate gene for this  QTL
because of:
-  its chromosomal location,
-  its paternal-specific expression,
-  its effect on myogenesis.8
I. Chromosomal location of IGF2
The chromosomal location of IGF2 in pigs was unknown at the time the QTL was
discovered.  However, it was suspected to co-localize with the QTL because of its
position in the human genome.  Indeed, IGF2 was  known  to  map  to  human
chromosome 11p15.5  and  bidirectional chromosome painting  had  shown  that
HSA11pter-q13  corresponds  to  SSC2p  (Goureau  et  al., 1996). A  FISH
(fluorescent in situ hybridisation) experiment was consequently set up to confirm
the assignment of IGF2 to SSC2p. In this experiment, a  porcine BAC  clone
containing IGF2 was hybridized to porcine metaphase chromosomes and gave a
consistent signal on the distal end of chromosome 2p (band 2p1.7) (Jeon et al.,
1999). This confirmed that IGF2 and the QTL both mapped to the distal end of
pig chromosome 2.
II. Effects of IGF-II
Insulin-like growth factor II (IGF-II) is a 67  amino  acid-long,  single  chain
polypeptide belonging to the insulin family. This family also includes insulin and
insulin-like growth factor I (IGF-I). The genes coding for these three proteins are
orthologs (i.e. they have evolved from a common ancestral gene) and are the result
of two duplication events. The first duplication  occurred approximately  600
million years ago and gave raise to insulin and a common ancestor for the two
insulin-like growth factors. This ancestor then led to the genes coding for IGF-I
and IGF-II after an additional duplication event that took place around 300 million
years ago (Froesch et al., 1985).
IGF-II and insulin show 47% sequence identity  at  the  amino  acid  level.
Furthermore, they have the same three-dimensional structure since they have the
same three interchain disulphide bridges and hydrophobic core (O’Dell &  Day,
1998).
Receptors
IGF-II exerts its biological effects through three receptors:
IGF-I receptor
The IGF-I receptor binds IGF-I with highest affinity but it binds also IGF-II (with
2-15 times lower affinity) and insulin (with 100-500 lower affinity). It is present
in a large variety of tissues where it mediates most of the effects of both IGF-I and
IGF-II (Cohick & Clemmons, 1993).
IGF-II receptor
The IGF-II receptor has a high affinity for IGF-II. It can also bind IGF-I but with a
100 to 500 times lower affinity and it does not bind insulin at all. This receptor is
mainly known for its clearance role; hence, it internalizes IGF-II upon binding and
transports it to the lysosomes for degradation (Jones & Clemmons, 1995).  In
addition, it has been demonstrated to mediate part of the physiological actions of
IGF-II e.g. on myosarcoma cell motility (Minniti et al., 1992) and on extravillous9
trophoblast cell migration (McKinnon et al., 2001). The IGF-II receptor possesses
two binding sites for mannose-6-phosphate (Man-6-P) in  addition to  its  IGF-II
binding  site  and  is  therefore also  known  as  cation-independent mannose-6-
phosphate receptor. These Man-6-P sites mediate the  transport  of  lysosomal
enzymes from the Golgi apparatus to  the pre-lysosomes and the endocytosis of
ligands containing Man-6-P e.g. thyroglobulin.
Insulin receptor
The insulin receptor binds both insulin and IGF-II, but it has a ten times  lower
affinity for IGF-II compared to insulin. It was shown to mediate part of the growth
promoting  function  of  IGF-II  in  human  and  mouse  fetus  (Louvi,  Accili  &
Efstratiadis, 1997). The insulin and IGF-I receptors are structurally highly similar
heterotetrameric glycoproteins composed of two alpha and two beta subunits
(α2β2). Hybrid insulin/IGF-I receptors composed of one αβ IGF-I half receptor and
one αβ insulin half receptor have even been found on cells expressing both types
of receptors (Jones & Clemmons, 1995).
Binding Proteins
More than 99% of circulating IGFs  are bound  by  Insulin-like Growth  Factor
Binding  Proteins  (IGFBP)  (Dupont  et al., 2003).  Up  till  now,  six  IGFBP
(IGFBP1-6) have been described. They are characterized by conserved amino- and
carboxy-terminal but each of them has a unique central domain. Their main role is
to modulate the biological effects of the IGFs by (1) maintaining a reservoir of
IGFs in circulation, (2)  transporting IGFs  across the  capillary membrane, (3)
localizing the IGFs to specific tissues, (4) modulating binding of the IGFs to their
receptors and (5) prolonging the half-life of the IGFs (Wood, 1995). In addition,
they have also been shown to have various IGF-independent actions e.g. as growth
modulators (Mohan & Baylink, 2002).
Biological actions
IGF-II acts both through endocrine and autocrine / paracrine pathways and has been
shown to:
-  Promote feto-placental growth: IGF-II  has  metabolic,  mitogenic  and
differentiative actions on a wide range of fetal tissues and on the placenta
(Jones & Clemmons, 1995). Experiments using  transgenic mice  have
proven that IGF-II is a potent fetal growth factor. DeChiara, Robertson &
Efstratiadis (1990) showed, for example, that knockout Igf2 mice weigh
only 60% of the normal weight at birth.
-  Promote both cell proliferation and cell differentiation. Hence,  Florini
and co-workers (1991) demonstrated that autocrine secretion of  IGF-II
plays  a  major  role  in  skeletal  muscle  cell  differentiation. Oksbjerg,
Gondret  &  Vestergaard  (2004)  reported  that,  in  muscle  cells,  the
stimulation  of  proliferation  and  differentiation  by  the  IGFs  is
concentration- and time-dependant.
-  Prevent apoptosis: this has been shown e.g. in cultures of  myoblast,
neurons and oligodendrocytes (Jones & Clemmons, 1995)10
-  Mediate insulin-like effects e.g. on glucose and fat metabolism (Jones &
Clemmons, 1995).
-  Increase cell motility (and hence malignancy) in myosarcoma (Minniti et
al.,  1992),  to  increase migration  of  extravillous  trophoblastic  cells
(McKinnon et al., 2001).
In  addition,  over-expression  of  IGF-II  has  been  shown  to  cause  cell
hyperproliferation associated with tumour formation (Wood, 1995).
III. Imprinting
Definition
Genomic imprinting has been defined as “an epigenetic modification that  is
parental-origin specific, and/or preferential expression of a specific parental allele
in somatic cells of the offspring” (Feinberg, Cui  &  Ohlsson,  2002). The term
“epigenetic” literally means outside  conventional  genetics  (Jaenisch  &  Bird,
2003); thus, epigenetic modifications are modifications  of  the  chromatin (e.g.
histone acetylation, DNA methylation) without modification of the DNA sequence
(Wilkins & Haig, 2003).   Those modifications are heritable trough  many  cell
divisions but can also be reset (at least in germline).
Transmission of imprints
The exact nature of the primary  epigenetic modification(s) responsible for  the
establishment of imprinting is  still  unknown. Nevertheless, Li  and co-worker’s
(1993) study on knockout mice has proven that methylation is necessary at least
for  maintaining  imprinting.  The  imprints  causing  parent-of-origin  specific
expression have to be  reset at  each generation in  order to  correspond to  the
germline of the new individual. Hence, imprints go through a three-step life cycle
(Reik & Walter, 2001a):
Erasure
This first step occurs in the primordial germ cells. Imprints inherited from the
parents are removed and DNA is totally unmethylated.  Nuclear transplantation
experiments in mouse have shown that Igf2 is silenced at this stage whereas H19
is expressed (Labosky et al., 1994).
Establishment
The new imprints specific to the germline (oocyte or sperm) are set up at a late
fetal stage in males and after birth in females. De novo methylation takes place and
results in overall higher methylation in male germ cells than in oocytes.
Maintenance
The new imprints have to be transmitted to both daughter cells at mitoses. This is
more challenging than it first appears as the  new  imprints  have  to  resist  the
genome-wide  demethylation  occurring  after  fertilization  and  the  de  novo
methylation taking place after implantation.11
(Epi)genetic characteristics of imprinted genes
Clusters
Eighty percents of imprinted genes are found in clusters. Genes linked in the same
cluster are believed to be co-regulated (Reik &  Walter, 2001a), notably through
Imprinting Control Regions (ICR). These are CpG-rich cis-acting elements that are
found associated to approximately 50% of the known imprinted genes and are
essential for the correct imprinting to occur (Fergusson-Smith &  Surani, 2001).
ICRs can be up to several kilobases long and are differentially methylated (usually
the maternally-derived ICR is methylated) (Delaval & Feil, 2004).
CpG islands
CpG islands are not an exclusive characteristic of imprinted genes but imprinted
genes are much more often associated with CpG islands than non-imprinted genes
(88%  versus  47%  in  mouse)  (Reik  &  Walter,  2001a).  Gardiner-Garden and
Frommer (1987) defined CpG islands as  DNA  stretches  fulfilling  the  three
following criteria:
-  length > 200 bp,
-  G + C content > 50%,
-  Observed CpG / Expected CpG > 0.6.
Direct repeats
The presence of tandem direct repeats associated to  GC-rich  sequences is  a
common characteristic among many imprinted genes. These repeats have  been
suggested to attract the methylation  machinery  by  mimicking  foreign  DNA
structure. Indeed, DNA methylation has been proposed to have evolved to protect
the host against the spreading of transposons and endogenous retroviruses. The
methylation and subsequent heterochromatization of the tandem repeats could lead
to spreading of methylation to the nearby GC-rich region. Nevertheless, deletion
experiments realized with H19 transgenes have shown that the  tandem  repeats
alone are not sufficient to cause allele-specific methylation (Reik  &  Walter,
2001a).
Except for their association with imprinted genes, the repeats themselves do not
have much in common. Their sequence, number of repetitions, length,  position
relatively to the gene, position relatively to the CpG island or DMR (differentially
methylated region) varies. Consequently, if they are involved in  the acquisition
and/or the maintenance  of  differential methylation  they  would  probably  act
through their organization. This could be done by:
-  Influencing the DNA secondary structure
-  Being recognized by protein complexes, e.g. methyltransferase
DNA methylation
DNA methylation has been shown to  be a key element to  maintain imprinting
(Brannan  &  Bartolomei,  1999;  Tilghman,  1999).  In  eukaryotes,  methylation
occurs on the carbon at position 5 of cytosines found in CpG dinucleotides (and
much more rarely in CpNpG trinucleotides) (Strachan & Read, 1999).12
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The resulting 5-methylcytosines are unstable and tend to deaminate into thymines.
This phenomenon has resulted in a decrease of the frequency of CpG dinucleotides
in the genome over time so that the actual observed frequency only corresponds to
23% and 19% of the expected frequency in human and mouse,  respectively
(Fazzari & Greally, 2004).
The  majority  of  known  imprinted  genes  have  been  shown  to  contain
differentially  methylated  regions  (DMR).  These  CpG-rich  regions  can  be
methylated on the  active or  silenced allele  and  can  contain  various  types  of
regulatory  elements  like  enhancers,  repressors  and  chromatin  boundaries.
Differential methylation results in allele-specific gene expression by modifying the
protein-DNA interactions. Indeed, the addition of a methyl group to the cytosine
modifies the aspect of the major groove of the DNA (which contains most of the
DNA-protein recognition sites) (Constância et al., 1998; Fazzari & Greally, 2004)
and can consequently:
- prevent binding of transcription factors,
- allow methyl CpG binding  proteins (e.g.  MeCP1,  MeCP2) to  bind.  These
proteins bind specifically to methylated DNA and mediate silencing through
histone deacethylation and  subsequent  chromatin  condensation  (Jones,  1999;
Jaenish & Bird, 2003).
Antisense transcripts
Fifteen percent of known imprinted genes have an antisense transcript. Amazingly,
this antisense gene is also imprinted and (almost) always  maternally silenced,
whether the sense transcript is maternally or paternally expressed (Reik & Walter,
2001a). The hypothesis that the antisense transcript is important for the regulation
of the sense gene was recently proven for Air (antisense Insulin-like growth factor
2 receptor) (Sleutels, Zwart & Barlow, 2002) and Kcnq1ot1 (antisense Kcnq1)
(Thakur et al., 2004).
It  is  amazing  to  notice  that  if  (almost)  all  imprinted  antisense  genes  are
paternally transcribed, the majority of the DMRs are maternally methylated. Reik
& Walter (2001b) have linked these observations to the fact that the genome-wide
demethylation occurring after fertilization is  active on  the  paternally inherited
chromosomes but passive on the maternally inherited ones. Hence, they suggested
that this active demethylation could be an attempt from  the  mother’s side  to
remove paternal imprints. Paternal imprints would  then  have  evolved towards
another type of silencing mechanism i.e. antisense transcripts.
Asynchronous replication
Kitsberg and co-workers (1993) studied the timing of replication  of  imprinted
genes by in situ hybridization to interphase nuclei. They showed that replication
of imprinted genes is asynchronous and even allele-specific as the paternal allele
always replicates before the maternal allele.  Hence,  Kitsberg  and  co-workers
suggested that the different replication time  is  a necessary imprint  to  establish13
allele-specific gene expression (e.g. by changing the accessibility of the DNA for
methyltransferases).
Meiotic recombination
The observation that regions actively transcribed during gametogenesis are more
prone to recombination led Thomas and Rothstein (1991) to the hypothesis that
the sex-specific recombination frequencies observed at certain places of the genome
might be caused by sex-specific gene expression e.g. imprinting. Pàldi, Gyapay &
Jami (1995) suggested that chromatin is organized in higher-order structures that
are responsible for:
-  Asynchronous replication.
-  Different frequency of meiotic recombination between sexes:  actively
transcribed regions have a more “open” chromatin structure which allows
more recombinations (possibly because enzymes initiating crossing-overs
have a better access to the DNA).
-  Imprinting: genes display allele-specific expression if:
o  They have specific signals in their sequence.
o  Modifying enzymes can access those signals in one sex but not
in the other because of the different chromatin environment.
Regulation of expression at the IGF2 locus
IGF2  is  part  of  a  cluster  of  imprinted  genes  located  on  HSA11p15.5
(corresponding to SSC2p1.7).  Two ICRs (imprinted control regions) regulate the
imprinting of these genes. The first one, Kv ICR, controls the imprinting of the
centromeric subcluster which contains KCNQ1, KCNQ1OT1 and CDKN1C. The
second one, H19 ICR, is located 2-4  kb  upstream of  the  H19 promoter and
controls imprinting at the telomeric subcluster which contains H19 and IGF2 (Du
et al., 2003). These two genes are reciprocally imprinted so that in most tissues
H19 is maternally expressed (Bartolomei, Zemel & Tilghman, 1991) and IGF2 is
paternally expressed (DeChiara, Robertson &  Efstratiadis, 1991;  Nezer et  al.,
1999). Furthermore, Li et al. (1998) suggested that the human H19 gene is  an
antagonist of IGF2 expressivity in trans. The mechanisms controlling imprinting
at the IGF2-H19 domain are complex and appear to  be  tissue-specific. In  the
endoderm, expression of IGF2 and H19 depends on activation of their promoters
by a set of shared enhancers located 3’ of H19 (Leighton et al.,  1995). On the
maternal chromosome, the unmethylated H19 ICR is bound by CCCTC-binding
factors (CTCF). This creates a chromatin boundary which isolates the  IGF2
promoters from the endodermal enhancers and results in  silencing of IGF2 and
expression of H19. On the paternal chromosome, methylation of the ICR prevents
CTCF from binding  which results in  activation of the IGF2 promoters by  the
endodermal-specific enhancers and IGF2 transcription (Bell &  Felsenfeld, 2000;
Hark et al., 2000;  Kanduri et al.,  2000a, b).  In addition,  the methylated ICR
directs methylation and subsequent silencing of the H19 promoter (Srivastava et
al., 2000) (Figure 1).  The situation appears to be more complex in mesodermal
tissues. In addition to mesodermal-specific enhancers located 3’ of H19 (Ishihara et
al., 2000), a series of other control elements have also  been  found  as  e.g. a
silencer located in DMR1 (IGF2 intron 3) (Eden et al., 2001)  and  a  muscle-14
specific silencer situated in the IGF2-H19 intergenic region (Ainscough et al.,
2000).
Figure  1
Representation
of the boundary
model
explaining
imprinting  at
the  IGF2-H19
locus. The  H19
ICR  is
unmethylated
on the  maternal
chromosome
and  is
consequently
 bound by CTCF.   This  creates  a chromatin  boundary  that  prevents  the  endodermal
enhancers (represented as triangles)  to activate  IGF2 expression.  The promoter  of H19
is  unmethylated  and  its  expression  can  hence  be  activated  by  the  endodermal
enhancers. On the contrary, the H19 ICR is  methylated  on  the  paternal  chromosome
(methyl groups are represented as stars). This methylation spreads to the H19 promoter
which becomes silenced. In addition CTCF cannot bind  to the methylated  ICR and the
endodermal enhancers can activate transcription of IGF2 (modified from Rand & Cedar,
2003).
At imprinted loci, the level of transcription of the transcribed allele  is  still
controlled by transcription factors like at non-imprinted loci.  Most  information
available on the regulation of IGF2’s four promoters (P1-4) (Sussenbach 1989; van
Dijk et al., 1991) comes from studies made in different human liver cell lines.
Hence,  promoter  P1  has  been  shown  to  be  activated  by  the  ubiquitous
transcription factor Sp1 (Rodenburg, Holthuizen & Sussenbach, 1997) and by the
CCAAT/enhancer binding protein (C/EBP) (van Dijk. et al., 1992). Promoters P3
and P4 have been shown to be regulated by the zinc finger transcription factors
Egr-1 and WT1. These two proteins bind to the same DNA element but binding of
Egr-1 results in  transcriptional activation whereas binding  of  WT1  results  in
transcriptional  repression  (Bae  et al., 1999; Lee et al.,  1998).  In  addition,
Rietveld et al. (1999) have demonstrated that  transcription from  promoter P3
responds to AP-2 binding so that overexpression of AP-2 results in activation of
P3 in cells with low endogenous level of AP-2 and repression of P3 in cells with
high endogenous level of AP-2. P3 has also been shown to be activated by  the
zinc finger oncogene PLAG1 (Zatkova et al., 2004). Finally, Sp1 was shown to
bind to promoter P4 and to cooperate with Egr-1 to mediate maximal activity of
this promoter (Lee, Park & Lee, 2001). The regulation of IGF2 transcription in
skeletal muscle cells has been less studied and is  poorly understood. However,
Erbay et al. (2003) have demonstrated that the Ser/Thr kinase mTOR  initiates
myoblast differentiation by regulating the expression of IGF2. In addition, Zhang
et al. (1998) have suggested that AP-2 may contribute to IGF-II overexpression in
an embryonal skeletal muscle tumor (rhabdomyosarcoma).15
Aims of the thesis
The objectives of this thesis were:
-  To identify the causative mutation(s) for  a  major  QTL  in  the  pig
influencing muscle growth, fat deposition and heart size  located  on
SSC2p.
-  To characterize the molecular mechanism(s) through which the mutation
exerts its effects.16
Methods
I. Transient transfection
This  method  can  be  used  to  determine  if  a  DNA  element  is  involved  in
transcriptional regulation of gene expression e.g. if it acts as promoter or enhancer.
Firstly, the element of interest is cloned in a plasmid containing a reporter gene
which expression can be easily assayed (e.g. luciferase, green fluorescent protein,
chloramphenicol acetyl transferase).  If the element is a putative promoter, it will
be inserted in a plasmid containing a strong enhancer (e.g. SV40 enhancer). On the
other hand, if the experimentator wants to test a supposed enhancer or silencer, it
will be cloned in a plasmid containing a promoter. In this  case, it  is  generally
recommended  to  use  the  homologous  promoter.  Secondly,  the  plasmid  is
transfected into a suitable cell line. This can be done by a biochemical (e.g. cation
lipid,  calcium  phosphate),  physical  (e.g. electroporation) or  virus-mediated
method. It is important to simultaneously transform the cells with a control vector
(expressing a different reporter) to be able to monitor differential cell growth and
transfection efficiency. Finally, the activity of the reporter is assayed after one to
four days incubation and the observed reporter signal is normalized to the control.
II. Electrophoretic Mobility Shift Assay (EMSA)
EMSA  is  a  standard  biochemical  in  vitro method  to  detect  protein-DNA
interactions  (Fried  &  Crothers,  1981).  This  assay  is  based  on  the  fact  that
migration of DNA through a native polyacrylamide gel is  retarded upon protein
binding. First, a short double stranded DNA fragment (called the  probe)  is
radioactively labelled. Second, the probe is incubated with proteins to allow DNA-
protein complexes to form. Proteins from diverse origins can be used in  EMSA
e.g. nuclear or whole-cell extracts from cells or  tissues  (Dignam,  Lebovitz &
Roeder, 1983) and purified recombinant proteins. Third, the protein-DNA binding
reactions are electrophoresed on a native polyacrylamide gel to  separate free and
protein-bound DNA. After autoradiography, the band corresponding to the DNA-
protein complex appears higher on the gel compared to the free probe; the probe
has also been “shifted” (Fig. 2).  The  migration  of  the  DNA-protein complex
depends mainly on the charge, shape and multimeric state of the protein. The
specificity of the obtained complexes has to be tested by the addition of an excess
of cold probe to the binding reaction. If the protein binds specifically it has the
same affinity for the cold and for the radioactively labelled probe. Hence, both
probes will compete for its binding and as the cold probe is in large molar excess
there will be no protein left to bind to the labelled probe, which results in  the
disappearance of the complex.17
Figure 2 Hypothetical EMSA. The free (unbound) probe as well as two specific  and one
unspecific complex are represented (modified from Carey & Smale, 2000)
The major advantages of EMSA are its simplicity and its high  sensitivity.  In
addition, it allows the  detection of  complexes of  different composition,  each
complex appearing as a band with a specific migration. Furthermore, EMSA gives
the possibility to check the identity of proteins included in a complex by  using
antibodies. Hence, a specific antibody can be added to the protein-DNA binding
reaction and its binding to the protein will result in an antibody-protein-DNA
complex  which  gel  migration  will  be  even  more  retarded (this  is  called  a
supershift). Alternatively, the antibody can cover the DNA binding site of the
protein and thereby prevent the formation of  the  complex,  resulting  in  the
disappearance of the shifted band (Carey & Smale, 2000).
III. DNase I Footprinting
DNase I footprinting allows the detection of protein-DNA interactions in vitro
(Galas and Schmitz, 1978). This method is based on the  principle that  DNA
regions bound by proteins are protected from digestion by DNase I. Basically, a
double-stranded DNA probe corresponding to the region of interest is radioactively
labelled on one end and used to set up two parallel reactions: one with proteins,
the other without. After incubation, a specific amount of DNase I is added to both
reactions so that each DNA molecule is cut only once. DNase I cuts randomly, and
in the absence of proteins the  probe  will  be  digested  in  a  series of  labelled
fragments ranging from one bp to full length probe. On the other hand, if DNA-
protein complexes form, the DNA bound by the proteins will not be accessible to18
the enzyme and this will result in the absence of DNA fragments of specific sizes.
Both reactions are then run on  a denaturing polyacrylamide gel to  separate the
DNA fragments according to their length.  After autoradiography of the gel,  the
probe incubated without proteins will appear as a continuous series of bands. The
probe incubated with proteins will also appear as a series of bands, but if protein-
DNA complexes have formed the areas corresponding to  the complexes will  be
devoid of bands. Those regions are called “footprints” (Carey &  Smale,  2000).
Usually, a Maxam-Gilbert sequencing reaction of the probe is  run together with
the DNase I digestions to enable the localization of the footprints (Fig.  3).  The
main advantage of this method is that it  gives the approximate binding  site  of
each protein binding to the probe. Furthermore, it is possible to analyse a quite
long DNA region in a single experiment (the probes are generally at least 300 bp
long).
Figure  3  Hypothetical  DNase  I
footprinting experiment  allowing
the  detection  of  two  protected
regions. Footprint 1 appears as  a
region  devoid  of  bands  whereas
in footprint 2 the bands are only
weakened compared to  the  ones
from the probe incubated  without
proteins.  A  ladder  (which  is
usually  a  Maxam-  Gilbert  A+G
sequencing  reaction)  is
electrophoresed together  with the
digested  probes  to  allow
localization of the footprints.19
Results and discussion
I. Comparative sequence analysis of the INS-IGF2-H19 gene
cluster in pigs (Paper 1)
The aim of this work was to further characterize  the  region  containing  the
mutation(s) causing the QTL. Here we report the sequence analysis of two  pig
contigs. The first one is 32 kb long and contains the  five  last  exons  of  TH
(Tyrosine hydroxylase) as well as the entire INS (insulin) and IGF2 genes. The
second one contains H19 and covers 56 kb.
We started by characterizing the order and the structure of INS, IGF2 and H19 in
pig and showed that they were identical to the ones in human. Hence, the gene
order is as follows: TH - 1.9 kb - INS - 0.7 kb - IGF2 - 88.1 kb - H19. IGF2 is
composed of ten exons (1-9 and 4b) that display high sequence identity between
human and pig (Fig. 4).
Figure 4. Genomic structure of porcine IGF2. The ten exons  of IGF2 are represented  as
boxes, black boxes correspond to the translated exons. The four promoters of IGF2 (P1-
4) are represented by arrows.
Nezer et al. (1999) showed that the coding region of IGF2 was identical between
pigs  with  different  QTL  genotypes.  We  therefore  suspected  the  causative
mutation(s) to lie in (a) regulatory element(s). Such elements tend to  be  well
conserved between species. This results from natural selection as individuals
carrying mutations in a regulatory element might display erratic gene expression
and lower fitness. Consequently, we compared our pig  sequence with  available
human and mouse sequences to find these conserved regions. We report  59
evolutionary conserved elements (outside exons, promoters and simple repeats) in
the INS-IGF2 region and 38 in the H19 region. Most of them have an unknown
function  but  some  have  been  assigned  an  important  role  in  regulating  the
expression of IGF2 in  human  and  mouse  e.g. DMR1,  CTCF  binding  sites,
endodermal enhancers (see introduction).
As expected from phylogenetic studies,  the  overall sequence similarity  was
higher between pig and human than between pig and mouse or human and mouse.
The pig sequence displays an amazingly large number of CpG islands: nine in the
INS-IGF2 region and sixteen in the H19 region. This can be put into relation with
the imprinting of the region. Indeed, CpG islands are more often found associated
with imprinted than with non-imprinted genes. The sequence is also characterized
by its low abundance of interspersed repeats. Once again, this could be related to20
the imprinting of IGF2 and H19 as the introduction of foreign sequence might
perturb the complex regulatory mechanisms controlling their expression.
Another important part of this  work was to  characterize IGF2 transcripts and
promoter  usage  in  different  fetal  and  adult  tissues.  We  found  that  IGF2
transcription is tissue- and development-specific and that it can be initiated from
four promoters (P1-4 located upstream of exons 1, 4, 5 and 6, respectively).
II. A regulatory mutation in IGF2 causes a major QTL effect on
muscle growth in the pig (Paper 2)
Nezer and co-workers (2003) refined the position  of the QTL to  a 250  kb-long
interval  between  the  markers  370SNP6/15  and  SWC9  (located  in  the  3’
untranslated region of IGF2). The only known paternally expressed genes mapping
to this region were insulin and IGF2. Therefore, we decided to re-sequence 28.6 kb
covering these two genes on 15 chromosomes  which  QTL  status  could  be
determined by progeny testing and marker-assisted segregation analysis. One of
the chromosomes (H254) appeared to be recombinant and allowed us  to  localize
the QTL downstream of the first exon of IGF2. Among the 258 polymorphisms
differentiating the 15 chromosomes, we only found one  SNP  co-segregating
perfectly with the QTL status of the chromosome. Therefore, this SNP, a GA
transition at position IGF2-intron 3-nt 3072, has to be the causative mutation. The
wild type allele (G) is associated with lower muscle mass and was therefore named
”q” while the mutant allele (A) causes higher muscle development and was called
”Q”.  The  quantitative  trait  nucleotide  (QTN)  is  located  in  an  evolutionary
conserved CpG island of unknown function. Consequently, we set up EMSA and
transient transfection experiments to uncover its mechanism of action. In addition,
we studied the methylation status of the CpG island by bisulphite sequencing.
We carried out EMSA  with  nuclear extracts from  three different cell  types
(C2C12 murine  myoblasts,  HepG2 human  hepatocytes and  HEK  293  human
embryonic kidney cells) and three different 27 bp-long probes:
-  q: wild-type probe
-  Q: mutant probe
-  q*: wild-type probe with a methylated CpG at the QTN. As methylation
is important for expression of imprinted genes we designed this probe in
order to test the influence of methylation on in vitro binding to the QTN.
We demonstrated the existence of a specific complex forming only with the wild-
type probe but not with the mutant probe nor with the methylated probe.
We transfected C2C12 myoblast cells with reporter plasmids expressing firefly
luciferase under the control of the thymidine kinase minimal promoter (TK) and a
578 bp-long fragment corresponding to the q or Q  genotype at the QTN. After
normalization, we found that the  q  insert  doubles  the  basal  TK  transcription
whereas the Q insert increases it seven times.21
Figure  5  Results  of  transient
transfection  experiments
carried  out  with  reporter
plasmids  expressing  firefly
luciferase under the  control  of
TK and an insert corresponding
to the q (q+TK)  or  Q  (Q+TK)
allele at the QTN. Results  were
normalised  to  a  Renilla
luciferase control  plasmid  and
are  expressed  as  relative
activities  to  a  plasmid
expressing  firefly  luciferase
under  the  sole  control  of  TK.
The  triple  asterisk  indicates
that  the  differences  observed
between the three plasmids  are
highly significant (P<0.01).
These results were quite difficult to conciliate with the results of the EMSA.
For this reason, we replaced the TK promoter with  IGF2 promoter 3  (P3) and
repeated the experiment. We choose P3 because it is the most actively transcribed
promoter in muscle cells and because it  is  influenced by  the QTN in  vivo (see
below). This time, we found that q reduces the basal P3 transcription with 70%,
whereas Q only reduces it with 30%.
Figure 6 Results of transient
transfections carried out like
in  Fig.  6  but  plasmids
express  luciferase  under  the
control of  the  P3  instead  of
TK.
Taken  together  with  the  EMSA  these  new  results  suggest  that  the  QTN
abrogates the binding of a repressor to  a cis-element. In addition,  our transient
transfection experiments illustrate how important it is to use a homologous rather
then a heterologous promoter in this kind of experiments.
We analyzed the methylation of the CpG island containing the QTN and found
that it is independent from the genotype at the QTN and from the parental origin
of the allele. However, we found that it is tissue-specific. Hence, on average, 26%
of the CpG dinucleotides are methylated in liver but only 3.4% are methylated in
skeletal muscle. Interestingly, the effect of the QTN is observed in muscle i.e. in a22
non-methylated tissue where the putative repressor is able to bind, but no effect is
seen in liver which is more methylated and where the putative repressor might
consequently not be able to bind so efficiently (according to the EMSA results). It
would be very exciting to analyze the situation in other tissues to  check if  this
association between methylation status and QTN effect holds.
We quantified the expression of IGF2 in vivo and found a significantly higher
expression in postnatal muscle samples from QQ and Q
patq
mat animals compared to
q
patQ
mat and qq animals. A weaker (but significant) difference could also be
observed in postnatal heart samples but not in postnatal liver nor in  any tested
prenatal tissue sample. Furthermore, we showed that IGF2 transcription  was
increased from all three promoters located downstream of the QTN (i.e. P2-4).
Finally, we  genotyped the progeny of 13  heterozygous sires (Qq) and of 50
homozygous sires (QQ or qq) and used this data in segregation  analyses.  We
found evidence for segregation in all heterozygous families but we could not find
any indication  of  segregation  among  progeny  sired  by  homozygous  males.
Furthermore, Jungerius et al. (2005) showed that the QTN also controls the QTL
for backfat thickness found in a Meishan x European Whites cross. In conclusion,
we demonstrated that the SSC2p QTL is caused by a GA transition at position
IGF2-intron 3-nt 3072 and that this mutation influences IGF2 expression. Hence,
we showed that, in  addition to  its  well-known fetal role, IGF2 is  involved in
postnatal muscle development.
III. IGF2 antisense transcript expression in porcine postnatal
muscle is affected by a quantitative trait nucleotide in intron 3
(Paper 3)
The aim of this study was to search for an IGF2 antisense (IGF2-AS) gene in pig,
and upon its existence to:
-  Characterize and quantify its transcript(s).
-  Examine its imprinting status.
-  Determine whether its expression was influenced by the IGF2 QTN.
We have shown by RT-PCR and RNase protection assay (RPA) that IGF2-AS
indeed  exists  in  pig.  Furthermore,  we  have  shown  that  it  has  two  different
transcription start sites; a major site located around IGF2 intron4-nt70 and a minor
site located approximately at IGF2 intron3-nt2294 (RPA results) or  intron3-
nt2205 (5’ RACE results). The 3’ end of the transcripts was mapped to position
IGF2 intron2–nt1236 by RACE. We found three different transcripts originating at
the major start site. These transcripts contain from three to five exons and share all
the same first and last exons (Fig. 7).23
Figure 7. Genomic structure of porcine IGF2 and multiple IGF2-AS transcripts
(a-d). Exons  are represented as boxes, black boxes correspond to  the translated
exons. Promoters are represented by arrows
Hence, we can conclude that the structure of IGF2-AS is  not  well conserved
between pig, human and mouse as this gene only has three exons in human and
four in mouse. However, some of the exons are quite well conserved between
species (Table 1).
Table1. Sequence identities between IGF2-AS exons in pig and  human or mouse.
Pig exon Human exon Mouse exon % Identity
1 1 72
2 2 60
5 3 63
Northern blot analyses revealed the existence of three transcripts in fetal muscle
(4.7 kb, 3.3 kb and 2.1 kb), two in fetal liver (3.5 kb and 2.1 kb) and one in fetal
kidney (3.3 kb). Surprisingly, the shortest band observed on the northern blot is
longer than the longest transcript predicted by the RT-PCR and 3’ RACE results.
This could result from preferential amplification of short truncated transcripts by
the nested RACE PCR or from a real heterogeneity of the transcripts.
Next, we  examined the  imprinting  status  of  IGF2-AS in  liver  and  muscle
samples from fetal,  3-weeks- and  4-months-old  piglets.  This  was  done  by
sequencing an A to C transversion at IGF2-AS exon2-nt32 which allowed us  to
discriminate between Q and q alleles at the QTN. We found that  IGF2-AS is
imprinted and only expressed from the paternal allele. This reflects the status at
other imprinted loci as most  antisense transcripts found in  imprinted genes are
maternally silenced. However, we should note that in muscle of 4-months-old pigs24
we could detect some transcription  from  maternal origin  which  indicates that
imprinting is partially released.
Finally, we used real-time PCR analysis to quantify IGF2-AS  transcripts in
muscle and liver from fetal, 3-weeks- and 4-months old pigs carrying the q or Q
allele at the QTN. Firstly,  we found that the expression of IGF2-AS decreases
noticeably after birth. Secondly, we found that in 3-weeks- and 4-months-old pig
muscle it depends on the genotype at the QTN. Indeed, at these stages, IGF2-AS
expression was significantly higher in Q than in  q  muscle samples. Hence, the
putative repressor binding at the QTN seems to influence both IGF2 and IGF2-AS
expression.
The function of IGF2-AS is still  unknown, but  it  has been suggested that it
could take part in the regulation of IGF2 expression. Indeed, it is noteworthy that
in pig as well as in human, the first and the last exon of IGF2-AS overlap part of
IGF2 exon 4 and the entire exon 3,  respectively. Consequently, IGF2-AS could
interfere with transcripts originating from P1 and P2.
IV. Molecular Characterization of a Region in IGF2 Intron 3
harbouring a Quantitative Trait Nucleotide affecting Muscle
Growth in the Pig (Paper 4)
The aim of this study was to:
-  Determine the binding site of the transcription factor binding to the QTN.
-  Characterize the CpG island containing the QTN.
-  Search for polymorphisms in the CpG island in human.
 We used EMSA to determine which nucleotides were important for the binding
of the putative repressor described in paper 2. Firstly, we performed EMSA with a
series of mutated probes to determine if these mutations could abolish formation
of the specific complex obtained with the wild-type probe. Secondly, we used the
mutated oligonucleotides in a competition assay to  determine if  they were still
able to compete against the wild-type probe. Taking these results together, we
found that the core binding site of the transcription factor is: 5’-GCTCG-3’. New
database searches did not reveal any factor with similar binding capacities.
DNase I footprinting of the 333 bp surrounding the QTN revealed two protected
regions, FP1 and FP2:
-  FP1  covers ~50 bp (from nucleotide position ~3027 to ~3076) and
includes the core binding site of  the  putative  repressor and  a  perfect
consensus AP-2 binding site.
-  FP2 is a ~ 30 bp-long footprint located ~20 bp upstream of FP1 (from
nucleotide position ~2981 to ~3008) and covers a putative Sp1 binding
site.
AP-2 has previously been shown to regulate IGF2 transcription from P3  and it
would be particularly interesting to  confirm it’s  binding  to  FP2.  Even  more
interesting would be to know if it binds DNA as a heteromer with  the putative
repressor. Hence, if they bind together, one could try to purify the repressor by co-
immunoprecipitating it with AP-2.25
Comparative sequence analyses of the CpG island containing the QTN  have
revealed a high sequence conservation between pig and human. This led us to the
hypothesis that the human DNA sequence could contain cis-elements involved in
muscle development, as is the case in pig. Therefore, we resequenced this region
in individuals with low versus high muscle mass. We discovered three SNPs and
one insertion/deletion. Interestingly, one  of  the  mutations  (CT, at  position
IGF2-intron 3-3462) lies in the putative AP-2 site included in FP2. Consequently,
we analysed the in vitro binding capacity of this site by running EMSA  with  a
wild-type and a mutant probe of the region. We were able to  detect binding  of
specific complexes with  similar  mobility  using  both  wild-type  and  mutant
sequences. It would be  very  interesting to  complement this  experiment by  a
supershift assay with AP-2-specific antibodies to confirm the involvement of this
transcription factor.26
Future prospects
This thesis summarizes the work that led to  the identification of the causative
mutation for a QTL influencing muscle development, fat deposition and heart size
in pig. In addition, it presents how we have started to uncover the  molecular
mechanisms by which this  QTN mediates its  effects. We have shown that the
mutation abrogates the binding of a putative repressor element, which results in
increased expression of IGF2 and IGF2-AS. We have also demonstrated that other
transcription factors bind DNA in the immediate vicinity of this  repressor. The
obvious next step in this project will be to clone and characterize this repressor.
Different methods could be considered to achieve this goal e.g. one-hybrid screen,
in vitro expression library screening, biochemical purification. In order to choose
the most appropriate approach, it is important to collect as much information as
possible on this transcription factor and  on  its  possible  interactions with  the
neighbouring DNA-binding factors. It is for example essential to know if it binds
DNA by itself or as a heteromer (as could be suspected from the DNase I
footprinting results). Indeed, some of the methods cited above are only capable to
deal with proteins binding as monomer, homodimer or homopolymer. In addition,
identifying a known factor binding DNA together with the repressor  could  be
extremely  useful;  antibodies  against  this  factor  could  be  used  to  co-
immunoprecipitate both factors as a first step towards purification of the repressor.
The identification of the gene  coding  for  a  transcription factor might  be  a
difficult task, but  it  would  be  worth  the  effort as  this  repressor could  have
fascinating therapeutic uses in the future. Indeed, it could be inactivated to increase
the expression of IGF2 in specific tissues. Our study has demonstrated that it is
active in skeletal muscle and heart but not in liver. In addition,  it  may also be
active in adipocytes as the IGF2-QTL also influences backfat thickness. Hence,
one could imagine to inactivate it in order to increase the muscle mass of patients
suffering from muscular degenerative diseases. Furthermore, it could be transiently
inactivated in patients confined in  bed to  avoid the muscle loss  accompanying
long periods of inactivity. In addition, if its activity is confirmed in adipocytes, it
could even be used to treat obese patients.
Finally, the identification of the causative mutation for the IGF2-QTL makes it
very  easy  to  select  pigs  with  the  favourable  Q  allele  to  breed  for  the  next
generations and hence to fix the mutation in  populations were it  is  present. In
addition, it will also facilitate the introgression of the mutant allele in pig breeds
where it is absent.  Indeed, when the introgression of a favourable gene variant is
based  on  linked  markers  there  is  always  a  risk  to  loose  it  because of  a
recombination between the markers  and  the  actual  causative  mutation.  This
problem has now been eliminated and makes  the  IGF2-QTL a  very  attractive
candidate for introgression into certain commercial populations.27
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